Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
- Associated Therapies
- -
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT03283696
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Miami School of Medicine, Miami, Florida, United States
🇩🇪Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)
- Conditions
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 80
- Registration Number
- NCT03263559
- Locations
- 🇺🇸
Texas Children's Hospital (Baylor), Houston, Texas, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Nicklaus Children's Hospital/University of Miami Children's Hospital, Miami, Florida, United States
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT03056339
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Umbilical Cord Blood Transplantation From Unrelated Donors
- Conditions
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 30
- Registration Number
- NCT03016806
- Locations
- 🇺🇸
Wilmot Cancer Institute, Rochester, New York, United States
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
- Conditions
- Interventions
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT02880293
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
- Conditions
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 170
- Registration Number
- NCT02790515
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT02732015
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma
- Conditions
- Interventions
- Drug: Fludarabine PhosphateDrug: MesnaDrug: CyclophosphamideRadiation: Total nodal irradiationBiological: T Cell-Depleted Hematopoietic Stem Cell TransplantationProcedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Peripheral Blood Stem Cell TransplantationDrug: Mycophenolate MofetilDrug: TacrolimusBiological: Rituximab
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 11
- Registration Number
- NCT02652468
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 320
- Registration Number
- NCT02436707
- Locations
- 🇨🇦
BCCA - Vancouver, Vancouver, British Columbia, Canada
🇨🇦Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.